Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

Abstract People with diabetes are at risk of chronic complications and novel biomarkers, such as Advanced glycation end-products (AGEs) may help stratify this risk. We assessed whether plasma low-molecular weight AGEs, also known as LMW-fluorophores (LMW-F), are associated with risk factors, predict...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrzej S. Januszewski, David Chen, Russell S. Scott, Rachel L. O’Connell, Nanda R. Aryal, David R. Sullivan, Gerald F. Watts, Marja-Riitta Taskinen, Philip J. Barter, James D. Best, R. John Simes, Anthony C. Keech, Alicia J. Jenkins
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/294b7a4d63544e699e028df0d5160f58
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:294b7a4d63544e699e028df0d5160f58
record_format	dspace
spelling	oai:doaj.org-article:294b7a4d63544e699e028df0d5160f582021-12-02T17:26:55ZRelationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes10.1038/s41598-021-98064-y2045-2322https://doaj.org/article/294b7a4d63544e699e028df0d5160f582021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98064-yhttps://doaj.org/toc/2045-2322Abstract People with diabetes are at risk of chronic complications and novel biomarkers, such as Advanced glycation end-products (AGEs) may help stratify this risk. We assessed whether plasma low-molecular weight AGEs, also known as LMW-fluorophores (LMW-F), are associated with risk factors, predict complications, and are altered by fenofibrate in adults with type 2 diabetes. Plasma LMW-F were quantified at baseline, after six weeks fenofibrate, and one year post-randomisation to fenofibrate or placebo. LMW-F associations with existing and new composite vascular complications were determined, and effects of fenofibrate assessed. LMW-F correlated positively with age, glycated haemoglobin (HbA1c), pulse pressure, kidney dysfunction and inflammation; and negatively with urate, body mass index, oxidative stress and leptin, albeit weakly (r = 0.04–0.16, all p < 0.01). Independent determinants of LMW-F included smoking, diastolic blood pressure, prior cardiovascular disease or microvascular complications, Caucasian ethnicity, kidney function, HbA1c and diabetes duration (all p ≤ 0.01). Baseline LMW-F tertiles correlated with on-trial macrovascular and microvascular complications (trend p < 0.001) on univariate analyses only. Six weeks of fenofibrate increased LMW-F levels by 21% (p < 0.001). In conclusion, LMW-F levels correlate with many risk factors and chronic diabetes complications, and are increased with fenofibrate. LMW-F tertiles predict complications, but not independently of traditional risk factors.Andrzej S. JanuszewskiDavid ChenRussell S. ScottRachel L. O’ConnellNanda R. AryalDavid R. SullivanGerald F. WattsMarja-Riitta TaskinenPhilip J. BarterJames D. BestR. John SimesAnthony C. KeechAlicia J. JenkinsNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Andrzej S. Januszewski David Chen Russell S. Scott Rachel L. O’Connell Nanda R. Aryal David R. Sullivan Gerald F. Watts Marja-Riitta Taskinen Philip J. Barter James D. Best R. John Simes Anthony C. Keech Alicia J. Jenkins Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
description	Abstract People with diabetes are at risk of chronic complications and novel biomarkers, such as Advanced glycation end-products (AGEs) may help stratify this risk. We assessed whether plasma low-molecular weight AGEs, also known as LMW-fluorophores (LMW-F), are associated with risk factors, predict complications, and are altered by fenofibrate in adults with type 2 diabetes. Plasma LMW-F were quantified at baseline, after six weeks fenofibrate, and one year post-randomisation to fenofibrate or placebo. LMW-F associations with existing and new composite vascular complications were determined, and effects of fenofibrate assessed. LMW-F correlated positively with age, glycated haemoglobin (HbA1c), pulse pressure, kidney dysfunction and inflammation; and negatively with urate, body mass index, oxidative stress and leptin, albeit weakly (r = 0.04–0.16, all p < 0.01). Independent determinants of LMW-F included smoking, diastolic blood pressure, prior cardiovascular disease or microvascular complications, Caucasian ethnicity, kidney function, HbA1c and diabetes duration (all p ≤ 0.01). Baseline LMW-F tertiles correlated with on-trial macrovascular and microvascular complications (trend p < 0.001) on univariate analyses only. Six weeks of fenofibrate increased LMW-F levels by 21% (p < 0.001). In conclusion, LMW-F levels correlate with many risk factors and chronic diabetes complications, and are increased with fenofibrate. LMW-F tertiles predict complications, but not independently of traditional risk factors.
format	article
author	Andrzej S. Januszewski David Chen Russell S. Scott Rachel L. O’Connell Nanda R. Aryal David R. Sullivan Gerald F. Watts Marja-Riitta Taskinen Philip J. Barter James D. Best R. John Simes Anthony C. Keech Alicia J. Jenkins
author_facet	Andrzej S. Januszewski David Chen Russell S. Scott Rachel L. O’Connell Nanda R. Aryal David R. Sullivan Gerald F. Watts Marja-Riitta Taskinen Philip J. Barter James D. Best R. John Simes Anthony C. Keech Alicia J. Jenkins
author_sort	Andrzej S. Januszewski
title	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
title_short	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
title_full	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
title_fullStr	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
title_full_unstemmed	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
title_sort	relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/294b7a4d63544e699e028df0d5160f58
work_keys_str_mv	AT andrzejsjanuszewski relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT davidchen relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT russellsscott relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT rachelloconnell relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT nandararyal relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT davidrsullivan relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT geraldfwatts relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT marjariittataskinen relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT philipjbarter relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT jamesdbest relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT rjohnsimes relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT anthonyckeech relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes AT aliciajjenkins relationshipoflowmolecularweightfluorophorelevelswithclinicalfactorsandfenofibrateeffectsinadultswithtype2diabetes
_version_	1718380780550356992

Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

Ejemplares similares